A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
 


Dr. LawrenceAnnable, BSc (Hons),Dip Stat
Professor


Research methodology
Psychiatric epidemiology
Research ethics


Ludmer Research and Training Building
1033 Pine Avenue West
Montreal
Quebec
H3A 1A1
514-398-7306
514-398-2964

lawrence.annable@mcgill.ca



Dr. Annable is a professor in the Department of Psychiatry at McGill University and a medical scientist at the McGill University Health Centre. He specializes in the design and statistical analysis of research studies in psychiatry, including randomized clinical trials of new treatments of psychiatric disorders and epidemiological investigations of risk factors for drug-induced side effects, in particular tardive dyskinesia. He teaches research methods in the Diploma Course in Psychiatry and tutors graduate students, postdoctoral fellows, and residents in this field. Dr. Annable is also associate editor (statistics) of the Journal of Psychiatry and Neuroscience. Another of his interests is research ethics, and he chairs the Psychiatry/Psychology Committee of the MUHC Research Ethics Board.


Undergraduate: University of Liverpool, UK
Postgraduate: University of Edinburgh, UK

Scientist: National Institute for Medical Research, London, UK


Fellow of the Royal Statistical Society, UK
American Statistical Association



Klein MB, Cooper C, Brouillette M-J, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J. CTN-194 Investigators: CTN-194 (PICCO): Design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemporary Clinical Trials 29:617-630, 2008.

Myhr G, Talbot J, Annable L, Pinard G: Suitability for short-term cognitive behavioural therapy. Journal of Cognitive Psychotherapy 2007;21:334-345.

Lal S, Thavundayil JX, Nair NPV, Annable L, Ng Ying Kin NMK, Gabriel A, Desjardins B, Schwartz G. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial. Journal of Psychiatry and Neuroscience. 31:271-27.

Margolese HC, Chouinard G, Kolivakis TL, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical neuroleptics. Part 2: Incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry. 50:70.

Carota A, Berney A, Aybek S, Iaria G, Staub F, Ghika-Schmid F, Annable L, Guex P, Bogousslavsky J. A prospective study of predictors of poststroke depression. Neurology 2005;64:428-433.

Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette's Syndrome. Journal of Clinical Psychopharmacology. 2002;22:31-39.

Margolese HC, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette’s syndrome treated with risperidone. Journal of Clinical Psychiatry. 2002;63:1040-1044.

Fontaine R, Chouinard G, Annable L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. American Journal of Psychiatry. 1984;141:848-852.

Chouinard G, Annable L, Fontaine R, Solyom L. Alprazolam in the treatment of anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacology. 1982;77:229-233.

Chouinard G, Annable L, Ross-Chouinard A. Factors related to tardive dyskinesia. American Journal of Psychiatry. 1979;136:79-83.